Home
Benign Prostatic Hyperplasia
SoracteLite
News
Company
Contact Us

Select Page

SoracteLite treatment presented at CIRSE 2019

Oct 8, 2018

Dr. G. Patelli reported SoracteLite treatment indications and clinical results at CIRSE 2019.

Click here to see the video of the presentation

Search

Search for:

Archive

Legal Notes
Privacy and Cookies Policy
Information for Customers and Suppliers

REGULATORY NOTICE USA

EchoLaser X4 is FDA cleared (510K) for tissue ablation in urology. Indications for use are however not disease specific. Although there’s solid clinical evidence, generated by a multitude of published clinical trials, confirming safety and efficacy of the treatment, patients must always discuss treatment options with a specialist doctor. It will ultimately be the specialist doctor who will determine if a patient is eligible for EchoLaser treatment.

© 2018 SoracteLite is a registered trademark in European Union by: Elesta SpA – tel.+39 055 88 26 807 – fax.+39 055 7766698
info@elesta-echolaser.com

The information published in this website is of general nature and only have an informative purpose. Under no circumstances can they replace any treatment or therapy prescribed by a physician or other healthcare professionals authorised by law. Any information on medical procedures and treatment descriptions in this website are intended for informative purposes only and do not provide the knowledge required for their application. All the indications provided at www.soractelite.info must always be backed up by the opinion of your doctor.